Business Context and Reporting Period
Company: Matinas BioPharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 6, 2025
Reporting Period: Single event date (August 6, 2025)
The Company filed a Certificate of Amendment to its Certificate of Incorporation with the Delaware Secretary of State to increase its authorized common stock. This action was approved by stockholders at the 2025 annual meeting held on June 23, 2025.
Key Financial Metrics
This filing is a corporate governance report regarding capital structure and does not contain financial performance data. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Authorized Share Increase: The number of authorized shares of common stock was increased from 250,000,000 to 500,000,000 shares.
- Effective Date: The amendment became effective immediately upon filing on August 6, 2025.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document strictly reports the procedural amendment to the Company's charter.
Investor Verification Checklist
- Verify the exact number of authorized shares increased (from 250 million to 500 million).
- Confirm the stockholder approval date (June 23, 2025) and the filing date (August 6, 2025).
- Review the full text of the Certificate of Amendment filed as Exhibit 3.1 for any additional terms or conditions not summarized in the 8-K.
- Check subsequent filings for any immediate issuance of shares from the newly authorized pool.